Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucanix maintenance therapy in advanced non-small cell lung cancer
2007-005234-36Phase 3Completed
- Sponsor
- NovaRx Corporation
- Start
- Apr 2008
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Lucanix maintenance with Placebo maintenance (2 arms). Primary endpoint: Overall survival. Started Apr 2008; status: completed.
02
Drugs
belagenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-005234-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005234-36.